McKechnie Duncan — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

McKechnie Duncan has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $5.66M.

Profile

McKechnie Duncan

Duncan McKechnie is identified in SEC filings as an executive at Vertex Pharmaceuticals Inc. In the filing with CIK 0002062139 dated January 26, 2026, he is listed as EVP, Chief Commercial Officer. Vertex is a global biotechnology company known for its cystic fibrosis therapies; as Chief Commercial Officer, McKechnie would be responsible for global commercial strategy and execution across Vertex’s portfolio.

RoleEVP, Chief Commercial Officer
Notability42/100

Board memberships

Awards & honors

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-07-07VRTXVERTEX PHARMACEUTICALS INC / MAS — Open-market sale1.5K$519.00$800K
2026-03-13VRTXVERTEX PHARMACEUTICALS INC / MAS — Open-market sale [10b5-1]2.6K$498.42$1.31M
2026-03-06VRTXVERTEX PHARMACEUTICALS INC / MAS — Open-market sale [10b5-1]2.4K$475.30$1.16M
2026-02-26VRTXVERTEX PHARMACEUTICALS INC / MAS — Open-market sale [10b5-1]2.4K$489.00$1.18M
2026-02-26VRTXVERTEX PHARMACEUTICALS INC / MAS — Open-market sale [10b5-1]2.5K$486.35$1.22M
2026-02-26VRTXVERTEX PHARMACEUTICALS INC / MAF — Tax withholding / forfeiture [10b5-1]873$485.11$424K
2026-02-19VRTXVERTEX PHARMACEUTICALS INC / MAF — Tax withholding / forfeiture1.1K$483.75$555K
2026-02-19VRTXVERTEX PHARMACEUTICALS INC / MAA — Grant or award5.0K$0.00
2026-02-18VRTXVERTEX PHARMACEUTICALS INC / MAF — Tax withholding / forfeiture2.3K$487.76$1.11M
2026-02-12VRTXVERTEX PHARMACEUTICALS INC / MAF — Tax withholding / forfeiture1.1K$468.41$528K
2026-01-26VRTXVERTEX PHARMACEUTICALS INC / MAA — Grant or award2.1K$0.00
2026-01-26VRTXVERTEX PHARMACEUTICALS INC / MAA — Grant or award4.7K$0.00

Companies — Last 90 Days

Frequently Asked Questions

Who is McKechnie Duncan?

Duncan McKechnie is identified in SEC filings as an executive at Vertex Pharmaceuticals Inc. In the filing with CIK 0002062139 dated January 26, 2026, he is listed as EVP, Chief Commercial Officer. Vertex is a global biotechnology company known for its cystic fibrosis therapies; as Chief Commercial Officer, McKechnie would be responsible for global commercial strategy and execu…

How many SEC Form 4 filings has McKechnie Duncan submitted recently?

1 primary Form 4 filings in the last 90 days, covering 1 company.

Has McKechnie Duncan been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 5 open-market sales ($5.66M) across all tracked filings.

Where can I see all of McKechnie Duncan's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live McKechnie Duncan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.